Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex in Multiple Sclerosis
NCT01610700Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- May 2001
- Primary completion
- Jul 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in multiple sclerosis (MS) (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at 6 weeks. Started May 2001; status: completed.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01610700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01610700.